These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38926480)

  • 1. Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.
    Basedow LA; Majić T; Hafiz NJ; Algharably EAE; Kreutz R; Riemer TG
    Sci Rep; 2024 Jun; 14(1):14782. PubMed ID: 38926480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users.
    Dafters RI; Hoshi R; Talbot AC
    Psychopharmacology (Berl); 2004 May; 173(3-4):405-10. PubMed ID: 12955295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy.
    Schmid Y; Bershad AK
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):490-499. PubMed ID: 38341085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.
    Parrott AC; Lasky J
    Psychopharmacology (Berl); 1998 Oct; 139(3):261-8. PubMed ID: 9784083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMA use and neurocognition: a meta-analytic review.
    Kalechstein AD; De La Garza R; Mahoney JJ; Fantegrossi WE; Newton TF
    Psychopharmacology (Berl); 2007 Jan; 189(4):531-7. PubMed ID: 17082969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neuropsychology of ecstasy (MDMA) use: a quantitative review.
    Zakzanis KK; Campbell Z; Jovanovski D
    Hum Psychopharmacol; 2007 Oct; 22(7):427-35. PubMed ID: 17896346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.
    Verheyden SL; Henry JA; Curran HV
    Hum Psychopharmacol; 2003 Oct; 18(7):507-17. PubMed ID: 14533132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between specific parameters of MDMA use and cognitive and psychopathological measures.
    Wagner D; Adolph S; Koester P; Becker B; Gouzoulis-Mayfrank E; Daumann J
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():32-7. PubMed ID: 25510880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits.
    Parrott AC; Lees A; Garnham NJ; Jones M; Wesnes K
    J Psychopharmacol; 1998; 12(1):79-83. PubMed ID: 9584971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relative contributions of ecstasy and cannabis to cognitive impairment.
    Croft RJ; Mackay AJ; Mills AT; Gruzelier JG
    Psychopharmacology (Berl); 2001 Jan; 153(3):373-9. PubMed ID: 11271410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence.
    Dafters RI; Duffy F; O'Donnell PJ; Bouquet C
    Psychopharmacology (Berl); 1999 Jul; 145(1):82-90. PubMed ID: 10445376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function.
    Curran HV; Verheyden SL
    Psychopharmacology (Berl); 2003 Aug; 169(1):91-103. PubMed ID: 12759801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study.
    McCann UD; Mertl M; Eligulashvili V; Ricaurte GA
    Psychopharmacology (Berl); 1999 Apr; 143(4):417-25. PubMed ID: 10367560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired executive function in male MDMA ("ecstasy") users.
    von Geusau NA; Stalenhoef P; Huizinga M; Snel J; Ridderinkhof KR
    Psychopharmacology (Berl); 2004 Sep; 175(3):331-41. PubMed ID: 15034712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4-methylenedioxymethamphetamine users.
    van de Blaak FL; Dumont GJH
    Hum Psychopharmacol; 2022 Jan; 37(1):e2811. PubMed ID: 34506649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of repeated treatment with MDMA on working memory and behavioural flexibility in mice.
    Viñals X; Maldonado R; Robledo P
    Addict Biol; 2013 Mar; 18(2):263-73. PubMed ID: 22260267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.